Title
Anxiety and panic disorder: First-line pharmacotherapy
Authors
Shruti Vihang Brahmbhatt, Akil Idrish Sunasara* & Mahavirsingh Rajput
Affiliation
Department of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara- 391760, Gujarat, India; *Corresponding author
Shruti Vihang Brahmbhatt - E-mail: dr.shruti1988@gmail.com
Akil Idrish Sunasara - E-mail: akilsunasara81@gmail.com, Phone: +91 9727834668
Mahavirsingh Rajput - E-mail: drvirranawat@gmail.com
Article Type
Research Article
Date
Received June 1, 2026; Revised June 30, 2026; Accepted June 30, 2026, Published June 30, 2026
Abstract
Anxiety and panic disorders are common psychiatric illnesses, but real-world data on first-line pharmacotherapy outcomes from Indian tertiary care settings remain limited. Therefore, it is of interest to evaluate prescribing patterns, efficacy, safety, and tolerability of first-line pharmacotherapy in 40 newly diagnosed patients with anxiety or panic disorder. Anxiety disorder accounted for 72.5% of cases, and SSRIs alone or combined with benzodiazepines were the most frequently prescribed treatment regimens. Favorable clinical outcomes were observed in 77.5% of patients, while adverse drug reactions were predominantly mild and did not require treatment discontinuation. Thus, SSRI-based first-line pharmacotherapy demonstrated good efficacy and tolerability, supporting guideline-based management of anxiety and panic disorders.
Keywords
Anxiety disorder; panic disorder (PD); first-line pharmacotherapy; selective serotonin reuptake inhibitors (SSRIs); benzodiazepines
Citation
Brahmbhatt et al. Bioinformation 22(6): 3425-3429 (2026)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
